Alligator Bioscience regains global rights from Janssen to CD40 agonistic antibody, ADC-1013 (JNJ-64457107)
Lund, Sweden, July 31, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that it has regained exclusive, worldwide rights from Janssen Biotech Inc. to develop and commercialize the CD40 agonistic antibody, ADC-1013 (JNJ-64457107), its lead tumor-directed immunotherapy candidate, in Phase I development for the treatment of metastatic cancer. The 2015 partnership agreement between Alligator and Janssen has been terminated as a result of a strategic portfolio decision by Janssen to prioritize other assets. Per Norlén, CEO of Alligator Bioscience, said: “Our ambition